Number of patients
|
264
|
200
|
64
| |
Age, years
|
≤ 60
|
164
|
129 (64.5)
|
35 (54.7)
|
0.159
|
> 60
|
100
|
71 (35.5)
|
29 (45.3)
| |
Sex
|
Male
|
171
|
128 (64.0)
|
43 (67.2)
|
0.895
|
Female
|
93
|
72 (36.0)
|
21 (32.8)
| |
Primary tumor location
|
Colon
|
163
|
126 (63.0)
|
37 (57.8)
|
0.457
|
Rectum
|
101
|
74 (37.0)
|
27 (42.8)
| |
Primary tumor differentiation
|
Well to moderate
|
206
|
155 (77.5)
|
51 (79.7)
|
0.713
|
Poor
|
58
|
45 (22.5)
|
13 (20.3)
| |
T stagea
|
1–3
|
157
|
122 (65.2)
|
35 (66.5)
|
0.707
|
4
|
86
|
65 (34.8)
|
21 (33.5)
| |
N stageb
|
0
|
103
|
78 (42.9)
|
25 (45.3)
|
0.814
|
1–2
|
135
|
104 (57.1)
|
31 (55.4)
| |
Timing of metastasis
|
Synchronous
|
171
|
136 (68.0)
|
35 (54.7)
|
0.052
|
Metachronous
|
93
|
64 (32.0)
|
29 (45.3)
| |
Number of metastatic tumors
|
1
|
140
|
102 (51.0)
|
38 (59.4)
|
0.501
|
2–3
|
99
|
78 (39.0)
|
21 (32.8)
| |
4–5
|
25
|
20 (10.0)
|
5 (7.8)
| |
Metastases diameter (cm)c
|
≤ 3
|
173
|
134 (68.0)
|
39 (61.9)
|
0.371
|
> 3
|
87
|
63 (32.0)
|
24 (38.1)
| |
Preoperative CEA (ng/mL)d
|
≤ 50
|
200
|
156 (81.7)
|
44 (73.3)
|
0.161
|
> 50
|
51
|
35 (18.3)
|
16 (26.7)
| |
Preoperative CA19-9 (U/mL)a
|
≤ 35
|
166
|
128 (68.8)
|
38 (66.7)
|
0.760
|
> 35
|
77
|
58 (31.2)
|
19 (33.3)
| |
Preoperative chemotherapy
|
Yes
|
122
|
98 (49.0)
|
24 (37.5)
|
0.108
|
No
|
142
|
102 (51.0)
|
40 (62.5)
| |
MSKCC-CRSe
|
0–2
|
162
|
127 (73.4)
|
35 (67.3)
|
0.390
|
3–5
|
63
|
46 (26.6)
|
17 (32.7)
| |